key: cord-0870000-gsjusv3m authors: Vaughn, Valerie M; Gandhi, Tejal; Petty, Lindsay A; Patel, Payal K; Prescott, Hallie C; Malani, Anurag N; Ratz, David; McLaughlin, Elizabeth; Chopra, Vineet; Flanders, Scott A title: Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study date: 2020-08-21 journal: Clin Infect Dis DOI: 10.1093/cid/ciaa1239 sha: 392eb88b5aa3c8ee807925d35a1741d7d51e23e0 doc_id: 870000 cord_uid: gsjusv3m BACKGROUND: Antibacterials may be initiated out of concern for bacterial co-infection in patients with COVID-19. We determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial co-infections in hospitalized patients with COVID-19. METHODS: Randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020-6/18/2020. Data were collected on early (prescribed within 2 days of hospitalization) empiric antibacterial therapy and community-onset bacterial co-infections (positive culture or diagnostic test within 3 days). Poisson generalized estimating equation models were used to assess predictors of empiric antibacterial use. RESULTS: Of 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric antibacterial use varied from 27%-84%. Patients were more likely to receive early empiric antibacterial therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00-1.08] per 10 years), had a lower body mass index (ARR: 0.99 [0.99-1.00] per kg/m (2)), had more severe illness (e.g., severe sepsis, ARR: 1.16 [1.07-1.27]), had a lobar infiltrate (ARR: 1.21 [1.04-1.42]), or were admitted to a for-profit hospital (ARR: 1.30 [1.15-1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased. CONCLUSION: The prevalence of confirmed community-onset bacterial co-infections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use. COVID-19, the disease caused by the SARS-CoV2 virus, frequently presents as a febrile respiratory illness that may progress to pneumonia and respiratory failure. [1] [2] [3] In the absence of bacterial co-infection, antibacterial therapy has no known benefit in patients with COVID- 19 . However, patients with COVID-19 may be at risk for concomitant bacterial infections that would require antibacterial treatment. 4 Data on bacterial co-infections are sparse and variable, with reports of co-infections occurring in 3-30% of patients with COVID-19. [5] [6] [7] [8] [9] [10] Specifically, patients with COVID-19 are often started empirically on antibacterials when first hospitalized. 2, 11 However, it's unclear if bacterial co-infections are present early during hospitalization or develop later, after additional hospital exposures. To guide efforts to improve antibiotic therapy, more data are needed on the prevalence of community-onset bacterial co-infections. In a multi-center cohort study of hospitalized patients with COVID-19 at 38 Michigan hospitals, we aimed to determine patterns and predictors of early empiric antibacterial therapy and community-onset bacterial co-infection. MI-COVID19 is a statewide multi-institutional collaborative quality initiative (CQI) sponsored by Blue Cross Blue Shield of Michigan and Blue Care Network 12 to improve care for hospitalized patients with COVID-19. Institutional participation in MI-COVID19 is voluntary. A c c e p t e d M a n u s c r i p t 6 The data abstraction and collection templates were adapted from the Michigan Hospital Medicine Safety Consortium (HMS). 13 Of the 92 non-critical access, non-federal hospitals in Michigan, 38 (41.3%) elected to participate in MI-COVID19. Hospitals participating in MI-COVID19 were diverse in terms of size, teaching status, and ownership structure ( Table 1) . Trained abstractors collected data via medical record review; data collection and quality assurance procedures have been previously described. 14 Our primary cohort of interest was hospitalized adults with positive COVID-19 PCR (polymerase chain reaction) testing during the 2020 COVID-19 surge in the state of Michigan. Patients were excluded if they were pregnant, <18 years-old, left against medical advice, were comfort care within 3 hours of hospitalization, or were transferred from another hospital. For patients with multiple hospitalizations, only the first was included. A pseudo-random sample of COVID-19 positive cases discharged between 3/13/2020 and 6/18/2020 from each hospital was included. When hospitals had abstractor capacity to include all eligible patients, they did. Hospitals unable to abstract all cases (e.g. due to high COVID-19 volumes) followed a pseudo-randomization procedure in which daily eligible cases were sorted by timestamp of discharge and included in order of smallest minute value until abstraction capacity was reached. Similar to prior studies, 15,16 data on included patients were collected from 90-days prior to admission until death or hospital discharge. Data collected included demographics, comorbidities, antibacterial use (daily inpatient utilization), daily signs and symptoms (e.g., A c c e p t e d M a n u s c r i p t 7 laboratory results, vital signs, organ support), radiographic results, and microbiologic data. Data were collected from medical records using a standardized data dictionary and operations manual and entered into the MI-COVID19 registry using a structured data collection template. The primary outcome was the percentage of patients prescribed early empiric antibacterial therapy (any intravenous or oral antibacterial on day 1 or 2 of hospitalization). Antibacterial therapy started after day 2 was not considered empiric as it may have been aimed toward hospital-onset infection. Empiric antibacterials were categorized as targeting a) communityacquired organisms only (defined using 2019 American Thoracic Society and Infectious Diseases Society of America guidelines to include ampicillin/sulbactam, cefotaxime, ceftriaxone, moxifloxacin, levofloxacin, ceftaroline; please see Appendix for details), 17 b) methicillin-resistant Staphylococcus aureus (MRSA), or c) Pseudomonas aeruginosa. Azithromycin in the absence of other antibacterial treatment was not included as many MI-COVID19 hospitals recommended its use as COVID-19 specific therapy. 18 We also calculated antibiotic duration based on daily administration and discharge prescriptions. The secondary outcome of interest was community-onset bacterial co-infection. Coinfections were identified by a) blood or respiratory culture positive for a typically pathogenic bacterium (for a list of excluded contaminants, see Appendix), b) positive Legionella pneumophila or Streptococcus pneumonia antigen, or c) positive Mycoplasma pneumonia or Chlamydophila pneumonia PCR test. We also report how many patients had a community-onset viral infection based on respiratory virus PCR testing. Co-infections were A c c e p t e d M a n u s c r i p t 8 considered community-onset if the positive culture or test was collected in the first three days of hospitalization. Variables of interest included: a) patient demographics; b) comorbidities; c) symptoms (e.g., cough); d) disease severity on admission (admission to intensive care, highest mode of respiratory support on day 1 or 2 of hospitalization, sepsis, severe sepsis, septic shock); and e) features potentially indicating bacterial infection (chest imaging showing lobar infiltrate, sputum production, elevated procalcitonin, elevated white blood cell count, elevated creactive protein [CRP]). Hospital-level variables included bed size, profit-type, and selfreported teaching status. Descriptive statistics (percentages and medians with interquartile range [IQR]) were used to characterize the cohort. To evaluate individual predictors associated with empiric antibacterial use or community-onset bacterial co-infection, we performed bivariable analyses using general estimating equation (GEE) Poisson models with robust standard errors and compound symmetry correlation structure, accounting for hospital clustering. We used Poisson models rather than logistic regression because the odds ratio only approximates the rate ratio when the outcome is rare. 19 For multivariable analysis, we used Poisson GEE models with backwards elimination starting with all variables that had a P-value of <0.10 in bivariable analyses and eliminating variables until all had P-value <0.050. CRP and procalcitonin were not missing at random (both variables were linked to hospital test availability and practice) and thus could not be imputed and were not included in the multivariable model. When describing hospital variation in empiric antibacterial use, we A c c e p t e d M a n u s c r i p t 9 included hospitals with at least 10 included COVID-19 positive patients (N=32 hospitals). All statistical tests were 2-sided; P-values <0.050 significant. SAS version 9.4 was used for analyses. We followed EQUATOR reporting guidelines (STROBE in Appendix). This project received non-regulated status prior to data collection by the University of Michigan Institutional Review Board. 3412 patients with COVID19 were eligible for inclusion. After pseudo-randomization, a total of 1705 patients from 38 hospitals were included. Patient characteristics are shown in Table 1 . The majority 56.6% (965/1705) of hospitalized patients with COVID-19 were prescribed early empiric antibacterial therapy ( Community-onset bacterial co-infections were confirmed in 3.5% (59/1705) of all patients, including 1.8% (31/1705) who had a positive blood culture and 1.7% (29/1705) who had a bacterial respiratory pathogen identified (from respiratory culture or non-culture diagnostic test). Community-onset bacterial infections occurred in 4.9% (47/965) of patients who received early empiric antibacterial therapy vs. 1.6% (12/740) of those who did not (P<.001), of which 33.3% (4/12) were subsequently started on antibiotics. Patients were more likely to have a community-onset bacterial infection if they were older, had a lower body mass index, had kidney disease, were admitted from a skilled nursing facility, were more severely ill (e.g., admitted to intensive care), or had more signs of a bacterial infection (e.g., higher white blood cell count; see Table 3 for details). Though 55.9% (19/34) of patients with a community-onset bacterial co-infection had a procalcitonin >0.5 ng/mL, so did 21.2% (186/876) of those without a community-onset bacterial co-infection. Thus, the positive predictive value of a procalcitonin >0.5 ng/mL was 9.3% for community-onset bacterial coinfection. In contrast, the negative predictive value of a procalcitonin ≤0.1 ng/mL was 98.3%. Thirty-two hospitals had at least 10 patients with COVID-19 included in MI-COVID19. Within these sites, the percentage of patients with COVID-19 who were prescribed empiric antibacterials varied from 27%-84%. Similarly, the percentage of patients receiving antibacterial therapy targeting community-acquired vs. anti-MRSA and/or antipseudomonal coverage also varied widely by hospital (Figure 1 ). Bivariable predictors of empiric antibacterial therapy are shown in Table 1 . On multivariable analysis, patients were more likely to receive early empiric antibacterial therapy if they were older, had a lower body mass index, had more severe disease (e.g., respiratory support, severe sepsis), had a lobar infiltrate, or were admitted to a for-profit hospital; patients admitted at a later date in the surge were less likely to receive empiric antibacterials (see Table 4 ). Of patients with COVID-19 who were prescribed empiric antibacterials and had their COVID-19 test return before the end of their hospitalization, 453/832 (54.4%) had their antibacterials stopped within 1 day after COVID-19 tests returned positive. Of the 379 that had antibacterials continued, only 28 (7.4%) had a confirmed community-onset bacterial co- In this large, multicenter cohort of patients hospitalized with COVID-19, we found 56.6% were treated with early empiric antibacterial therapy. Despite concerns that patients with COVID-19 might be at high risk for bacterial co-infections, we found only 3.5% of COVID-19 positive patients had a confirmed community-onset bacterial co-infection. Early empiric antibacterial use varied from 27% to 84% across hospitals and decreased over time. Similar to other studies, 4, 9, 11, 20 we found patients hospitalized with COVID-19 were often treated with early empiric antibacterials. Notably, we saw wide variability between hospitals in early empiric antibacterial use suggesting a need for a standardized approach to antibiotic use, diagnostic testing, and antibiotic stewardship in patients with COVID-19. Though the reasons for variation in empiric antibiotic use are unclear, variability could relate to existing antibiotic stewardship infrastructure or hospital culture. Supportively, we found for-profit A c c e p t e d M a n u s c r i p t 13 hospitals had more empiric antibacterial use even after adjustments. Other studies have found for-profit hospitals to have more variable quality of care; 21, 22 however, this has not been seen previously with hospitalized patients with pneumonia in HMS hospitals. 15 The fact that empiric antibacterial use was low in some hospitals suggests that unnecessary antibacterial use can be reduced even during pandemics; for example, by fast-moving, responsive, and well-supported antibiotic stewardship programs. 23 The high rate of empiric antibacterial use seen in patients hospitalized with COVID-19 must be considered in the context of the low prevalence of confirmed community-onset bacterial co-infection (3.5% in all patients; 4.9% in those who received antimicrobials). For every patient we identified as having a bacterial infection, nearly 20 without an identified infection also received empiric antibacterial therapy. These findings are similar to a twohospital study in the United Kingdom, which noted 3.2% of patients with COVID-19 had early confirmed bacterial infections (rising to 6.1% later during hospitalization), 7 and a study in New York which identified 3.6% of hospitalized patients with COVID-19 who had bacterial or fungal co-infections. 8 Other studies with systematic sampling have found bacterial coinfections in up to 30% of patients with COVID-19; though it is unclear the clinical significance as only 4% were severely or critically ill. 6 As with all retrospective studies of bacterial infection, we were limited by the poor sensitivity and incomplete use of diagnostic tests for bacterial infections. In particular, there was very low use of respiratory cultures in our cohort: only 7.7% of patients had a respiratory culture performed in the first three days of hospitalization. This is much lower than a prior study of patients hospitalized with pneumonia in HMS hospitals where 32.3% had respiratory cultures. 15 There are two potential reasons for the lack of respiratory A c c e p t e d M a n u s c r i p t 14 cultures. First, it is likely that fewer respiratory cultures-specifically more sensitive tests, such as induced sputum or bronchoalveolar lavage-were ordered due to concerns regarding aerosolization (and therefore healthcare worker safety) in patients with COVID- 19 . This may explain why we found other tests that do not create aerosols were used at similar or higher levels than in prior studies. For example, 54.8% of patients had non-culture respiratory pathogen testing (e.g., urine legionella antigen) compared to 15.9% in our prior study of patients hospitalized with pneumonia in HMS hospitals. 15 Our study represents a diverse look at early empiric antibacterial therapy across multiple hospitals. However, our findings must be considered in the context of limitations. First, we do not have complete data on secondary bacterial infections which may develop later during hospitalization. It is likely that, for some patients, bacterial co-infections develop later in hospitalization. 25 Second, we have limited data on patient outcomes given insufficient time since most were discharged, limiting our ability to assess the effect of early empiric antibacterial use on outcomes. Larger or prospective studies are needed to help determine who would benefit from empiric antibacterial therapy. Third, as noted above, we were limited by lack of systematic diagnostic testing. Fourth, we excluded azithromycin as an "antibacterial" because we were unable to distinguish between azithromycin use as an antibacterial vs. targeted therapy for COVID-19; thus, we likely underestimate the true prevalence of antibacterial overuse. Study strengths include data from multiple, diverse hospitals across a state that was surging at the time of data collection. Furthermore, the existing infrastructure from our prior pneumonia quality improvement work 13-15 allowed us to rapidly but rigorously collect and analyze data with experienced abstractors and analysts. M a n u s c r i p t 23 M a n u s c r i p t 28 .08) 0.09 Abbreviations: CI (confidence interval); IQR (inter-quartile range); CT (computed tomography) a Community-onset bacterial co-infections include any positive blood or respiratory culture or microbiological test obtained in the first three days of hospitalization (contaminants excluded). b Sepsis was defined as ≥2 of the following: temperature >38 °C or <36 °C, heart rate >90 beats/min, respiratory rate >20 breaths/min, and leukocyte count >12 × 109 cells/L or <4 × 109 cells/L or >10% immature bands. Severe sepsis was defined as sepsis plus evidence of organ dysfunction, defined as any of the following: systolic blood pressure <90 mm Hg (or initiation of vasopressors), lactate level >2 mmol/L, platelet count <100 × 109 cells/L, bilirubin level >2 mg/dL (without documentation of moderate or severe liver disease), creatinine level >2 mg/dL (without documentation of moderate or severe chronic kidney disease) or ventilatory support (i.e., non-invasive positive pressure ventilation or mechanical ventilation). Septic shock included any vasopressor requirement (vasopressors include angiotensin II, dobutamine, epinephrine, norepinephrine, phenylephrine, or vasopressin). c Not missing at random. 910 patients had a procalcitonin and 999 had a CRP. Missing data: 86 patients were missing body mass index, 23 patients were missing white blood cell count. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Critical Illness in Patients With COVID-19: Mounting an Effective Clinical and Research Response Co-infections in people with COVID-19: a systematic review and meta-analysis Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clinical Infectious Diseases Co-infection with respiratory pathogens among COVID-2019 cases Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting. Clinical Microbiology and Infection Bacterial and Fungal Co-Infections in COVID-19 Patients Hospitalized During the New York City Pandemic Surge A Deeper Dive Into Antibiotic Stewardship Needs: A Multihospital Survey The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial A modified poisson regression approach to prospective studies with binary data Clinical Characteristics of Coronavirus Disease 2019 in China Ethical issues in for-profit health care. For-Profit Enterprise in Health Care Making profits and providing care: comparing nonprofit, for-profit, and government hospitals Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck COVID-19: consider cytokine storm syndromes and immunosuppression A c c e p t e d M a n u s c r i p t M a n u s c r i p t 30 Empiric antibacterial therapy was defined as any intravenous or oral antibacterial therapy prescribed on day 1 or 2 of hospitalization. Does not include patients who received azithromycin only. Multivariable analysis used Poisson GEE models with backwards elimination starting with all variables that had P-value <0.10 in bivariable analyses and eliminating variables until all remaining had P-value <0.050. a Severe sepsis was defined as sepsis plus evidence of organ dysfunction, defined as any of the following: systolic blood pressure <90 mm Hg (or initiation of vasopressors), lactate level >2 mmol/L, platelet count <100 × 109 cells/L, bilirubin level >2 mg/dL (without documentation of moderate or severe liver disease), creatinine level >2 mg/dL (without documentation of moderate or severe chronic kidney disease) or ventilatory support (i.e., non-invasive positive pressure ventilation or mechanical ventilation). A c c e p t e d M a n u s c r i p t 32